IL-10 and class 1 histone deacetylases act synergistically and independently on the secretion of proinflammatory mediators in alveolar macrophages.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2021
2021
Historique:
received:
21
07
2020
accepted:
22
12
2020
entrez:
20
1
2021
pubmed:
21
1
2021
medline:
11
5
2021
Statut:
epublish
Résumé
Anti-inflammatory cytokine IL-10 suppresses pro-inflammatory IL-12b expression after Lipopolysaccharide (LPS) stimulation in colonic macrophages, as part of the innate immunity Toll-Like Receptor (TLR)-NF-κB activation system. This homeostatic mechanism limits excess inflammation in the intestinal mucosa, as it constantly interacts with the gut flora. This effect is reversed with Histone Deacetylase 3 (HDAC3), a class I HDAC, siRNA, suggesting it is mediated through HDAC3. Given alveolar macrophages' prominent role in Acute Lung Injury (ALI), we aim to determine whether a similar regulatory mechanism exists in the typically sterile pulmonary microenvironment. Levels of mRNA and protein for IL-10, and IL-12b were determined by qPCR and ELISA/Western Blot respectively in naïve and LPS-stimulated alveolar macrophages. Expression of the NF-κB intermediaries was also similarly assessed. Experiments were repeated with AS101 (an IL-10 protein synthesis inhibitor), MS-275 (a selective class 1 HDAC inhibitor), or both. LPS stimulation upregulated all proinflammatory mediators assayed in this study. In the presence of LPS, inhibition of IL-10 and/or class 1 HDACs resulted in both synergistic and independent effects on these signaling molecules. Quantitative reverse-transcriptase PCR on key components of the TLR4 signaling cascade demonstrated significant diversity in IL-10 and related gene expression in the presence of LPS. Inhibition of IL-10 secretion and/or class 1 HDACs in the presence of LPS independently affected the transcription of MyD88, IRAK1, Rela and the NF-κB p50 subunit. Interestingly, by quantitative ELISA inhibition of IL-10 secretion and/or class 1 HDACs in the presence of LPS independently affected the secretion of not only IL-10, IL-12b, and TNFα, but also proinflammatory mediators CXCL2, IL-6, and MIF. These results suggest that IL-10 and class 1 HDAC activity regulate both independent and synergistic mechanisms of proinflammatory cytokine/chemokine signaling. Alveolar macrophages after inflammatory stimulation upregulate both IL-10 and IL-12b production, in a highly class 1 HDAC-dependent manner. Class 1 HDACs appear to help maintain the balance between the pro- and anti-inflammatory IL-12b and IL-10 respectively. Class 1 HDACs may be considered as targets for the macrophage-initiated pulmonary inflammation in ALI in a preclinical setting.
Identifiants
pubmed: 33471802
doi: 10.1371/journal.pone.0245169
pii: PONE-D-20-22628
pmc: PMC7816993
doi:
Substances chimiques
IL10 protein, mouse
0
Il12b protein, mouse
0
Inflammation Mediators
0
Interleukin-12 Subunit p40
0
Interleukin-10
130068-27-8
Histone Deacetylases
EC 3.5.1.98
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0245169Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
J Virol. 2020 Mar 17;94(7):
pubmed: 31915279
J Immunol. 2000 Jul 1;165(1):292-6
pubmed: 10861064
Nat Med. 2005 Nov;11(11):1173-9
pubmed: 16244651
Blood. 2012 Nov 29;120(23):4653-62
pubmed: 22966168
N Engl J Med. 1987 Dec 17;317(25):1565-70
pubmed: 3317054
J Exp Med. 2008 Oct 27;205(11):2609-21
pubmed: 18838547
J Immunol. 2015 Feb 1;194(3):855-60
pubmed: 25596299
Immunol Rev. 2007 Dec;220:60-81
pubmed: 17979840
Signal Transduct Target Ther. 2017;2:
pubmed: 29158945
BMC Bioinformatics. 2017 Nov 29;18(1):529
pubmed: 29187165
Biochem Pharmacol. 2006 Nov 30;72(11):1423-31
pubmed: 16889755
Immunity. 2001 Jun;14(6):705-14
pubmed: 11420041
EMBO J. 2011 May 18;30(10):1977-89
pubmed: 21468030
Am J Respir Crit Care Med. 2008 Jul 1;178(1):34-41
pubmed: 18403723
Nat Rev Immunol. 2010 Mar;10(3):170-81
pubmed: 20154735
Biochem Pharmacol. 2005 Aug 1;70(3):394-406
pubmed: 15950952
Immunol Rev. 2008 Dec;226:205-18
pubmed: 19161426
Blood. 2000 May 15;95(10):3183-90
pubmed: 10807786
Infect Immun. 2001 Sep;69(9):5249-63
pubmed: 11500393
JAMA. 2016 Feb 23;315(8):788-800
pubmed: 26903337
J Biol Chem. 2006 Feb 17;281(7):4540-7
pubmed: 16371367
Vaccines (Basel). 2017 Oct 04;5(4):
pubmed: 28976923
J Biol Chem. 2002 Mar 15;277(11):9590-7
pubmed: 11777905
N Engl J Med. 2014 Jun 5;370(23):2191-200
pubmed: 24835849
Blood Cells Mol Dis. 1999 Oct-Dec;25(5-6):328-38
pubmed: 10660480
Nat Immunol. 2011 Jul 19;12(8):689-94
pubmed: 21772277
J Interferon Cytokine Res. 2007 Jun;27(6):453-62
pubmed: 17572009
JCI Insight. 2019 Aug 22;4(16):
pubmed: 31434802
J Immunol. 1998 Jun 15;160(12):5936-44
pubmed: 9637507
Crit Rev Immunol. 2012;32(1):23-63
pubmed: 22428854
Trends Immunol. 2019 May;40(5):447-462
pubmed: 30962001
J Immunol. 2010 Aug 1;185(3):1894-902
pubmed: 20610652
Infect Immun. 2005 Mar;73(3):1754-63
pubmed: 15731076
Nat Methods. 2012 Jun 28;9(7):676-82
pubmed: 22743772
J Exp Med. 2005 Oct 17;202(8):1131-9
pubmed: 16230478
Immunol Rev. 2004 Dec;202:96-105
pubmed: 15546388
Science. 1993 Apr 23;260(5107):547-9
pubmed: 8097338
Science. 2001 Aug 31;293(5535):1653-7
pubmed: 11533489
Genes Dev. 2007 Jul 15;21(14):1790-802
pubmed: 17639084
Cell Immunol. 1997 Mar 15;176(2):180-5
pubmed: 9073392
Respir Res. 2007 Oct 04;8:71
pubmed: 17916230
Eur J Immunol. 2005 Oct;35(10):2991-3001
pubmed: 16184516
Cell Signal. 2013 May;25(5):1228-34
pubmed: 23422584
Aging Cell. 2020 Apr;19(4):e13130
pubmed: 32170906
N Engl J Med. 2005 Oct 20;353(16):1685-93
pubmed: 16236739
Proc Natl Acad Sci U S A. 2010 Jul 13;107(28):12617-22
pubmed: 20616024
Nat Immunol. 2012 Jul 19;13(8):722-8
pubmed: 22814351
N Engl J Med. 2006 Apr 20;354(16):1671-84
pubmed: 16625008
J Immunol. 2012 Aug 15;189(4):1792-9
pubmed: 22786766
J Exp Med. 1994 Jun 1;179(6):1895-902
pubmed: 8195715
Mol Cell Biol. 2001 Oct;21(20):7065-77
pubmed: 11564889
J Immunol. 2000 Jun 1;164(11):5564-74
pubmed: 10820230
Proc Natl Acad Sci U S A. 2009 Apr 7;106(14):5761-6
pubmed: 19307576
FASEB J. 2018 Oct;32(10):5312-5325
pubmed: 29718706
Nat Genet. 2000 Jun;25(2):187-91
pubmed: 10835634
J Immunol. 2007 Jan 15;178(2):1164-71
pubmed: 17202381
Curr Biol. 2011 Jul 12;21(13):R488-93
pubmed: 21741580
PLoS One. 2012;7(2):e31080
pubmed: 22347433
F1000Res. 2015 Dec 17;4:
pubmed: 26918147
J Immunol. 1999 Apr 1;162(7):3749-52
pubmed: 10201887
JAMA. 2016 Jun 14;315(22):2406-14
pubmed: 27179988
J Neuroimmunol. 1995 Jul;60(1-2):165-8
pubmed: 7642744
J Trauma Acute Care Surg. 2018 Jul;85(1):148-154
pubmed: 29958249
Nature. 2001 Dec 20-27;414(6866):920-4
pubmed: 11780066
N Engl J Med. 2014 Oct 30;371(18):1695-703
pubmed: 25268516
Genes Dev. 2018 Oct 1;32(19-20):1309-1314
pubmed: 30228203